Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05116475
Other study ID # ALADDIN
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 30, 2022
Est. completion date February 2027

Study information

Verified date March 2024
Source Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Contact Ishak Senouci
Phone 0766185461
Email ishak.senouci@association-artic.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, multicenter, comparative, randomized placebo-controlled Phase III trial - patients with hormone-naïve prostate cancer and pelvic lymph nodes metastases


Description:

Standard of care for patients with prostate cancer (PC) with pelvic lymph nodes metastases is radiotherapy (RT) with long-term androgen deprivation therapy (ADT). . Darolutamide improves survival in men with castration-refractory non metastatic prostate cancer. We hypothesize that adding Darolutamide to ADT and RT could improve FFS for these high-risk patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 152
Est. completion date February 2027
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria: 1. . Newly diagnosed, histologically confirmed prostate adenocarcinoma 2. = 18 years old. 3. Initial staging with Pelvic MRI, body CT-scan/bone scan or Choline or PSMA PET-CT 4. Any T stage 5. N stage: N1 - Pelvis lymph nodes metastases (upper limit defined as the L4/L5 interspace). 6. Intention to treat with long-term androgen deprivation therapy (24 months). 7. Hormonal therapy with LH-RH agonist or antagonist is allowed up to 3months prior to randomization. 8. Able to receive protocol therapy and have life expectancy of at least 36 months, ECOG Performance Status (PS) 0-2. 9. . Blood counts at screening: hemoglobin = 9.0 g/dl, absolute neutrophil count = 1500/µl (1.5x109/l), platelet count = 100,000/µl (100x109/l ) (patient must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening). 10. Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) < 2.5 x upper limit of normal (ULN), total bilirubin < 1.5 x ULN (except patients with a diagnosis of Gilbert's disease), creatinine < 2.0 x ULN. 11. Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method during the study treatment and for 3 months after the end of the study treatment. 12. Written informed consent. 13. Willing and expected to comply with follow-up schedule. 14. Affiliated to the social security system. 15. Use of 5-a reductase inhibitors (finasteride, dutasteride) is allowed Exclusion Criteria: 1. Lymph nodes metastases outside of the pelvis 2. Bone or visceral metastases 3. Prior systemic therapy for locally-advanced prostate cancer except for LH-RH agonist or antagonist up to 3 months before randomization 4. Prior treatment with: - Second generation AR inhibitors such as enzalutamide, apalutamide (ARN-509), darolutamide (ODM-201) other investigational AR inhibitors - CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or - Oral ketoconazole - Use of estrogens, or AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) 5. Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomization. 6. Patients with QTor QTc interval > 450 ms on the ECG 7. Initiation of treatment with bisphosphonate or denosumab within 12 weeks before randomization. Patients receiving bone loss prevention treatment on a stable dose of e.g. bisphosphonate or denosumab for at least 28 days before randomization can continue the treatment during the study. 8. Known hypersensitivity to the study treatment (RT, ADT, darolutamide/placebo) or any of its ingredients. 9. Major surgery within 28 days before randomization. 10. Any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV or arterial thromboembolic event. 11. Uncontrolled hypertension as indicated by a resting systolic BP > 160 mmHg or diastolic BP > 100 mmHg at screening. Patients may be re-screened after adjustments of anti- hypertensive medications. 12. Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which chemotherapy has been completed > 5 years ago and from which the patient has been disease-free. 13. Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment. 14. Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease. 15. Participation in another interventional clinical trial and any concurrent treatment with any investigational drug 16. Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures. 17. Unable to swallow study medications and comply with study requirements. 18. Galactose intolerance, the Lapp lactase deficiency or glucose galactose-malabsorption 19. History of bilateral hip replacements making IMRT impossible 20. Contra-indications for the administration of any of the study treatments (RT, ADT, Darolutamide/placebo) or any of its ingredients. 21. Patient under guardianship, administrative tutorship and incapable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Darolutamide 300 mg
Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
Placebo of Darolutamide
Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.

Locations

Country Name City State
France Pôle Santé Léonard de Vinci Chambray-lès-Tours

Sponsors (2)

Lead Sponsor Collaborator
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie Bayer

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Failure-free survival FFS The failure-free survival is defined as the time from the date of randomization to clinical (new cancer-related symptoms), biochemical (PSA rising) or radiological (local relapse or new metastases) progression, death, end of 3-year follow-up period or lost to follow-up, whichever occurs first. 3 years
Secondary Metastasis-free survival rates To evaluate the metastasis-free survival rates 3 years
Secondary Progression free survival rate To evaluate the progression free survival rates 3 years
Secondary PSA response levels PSA response is defined by the rate of patients having a decrease of > 50% of their PSA level, as measured every 3 months from the date of randomization to the date of a documented biochemical relapse. 3 years
Secondary Overall survival rates Overall survival is defined as the time from the date of randomization to the date of documented death from any cause, end of 3-year follow-up period or lost to follow-up, whichever occurs first 3 years
Secondary Cancer-specific survival rates Cancer-specific survival is defined as the time from the date of randomization to the date of documented death from prostate cancer or complication from the treatment, end of 3-year follow-up period or lost to follow-up, whichever occurs first 3 years
Secondary Time to pain progression Time to pain progression is defined as the time from the date of randomization to the date of documented pain, end of 3-year follow-up period or lost to follow-up, whichever occurs first 3 years
Secondary Toxicities To evaluate toxicities (CTCAE v5.0) due to treatements 3 years
Secondary Quality of life of the patient Quality of life will be assessed using self-administered questionnaires (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire : EORTC QLQ-C30 v2) 3 years
Secondary Quality of life of the patient Quality of life will be assessed using self-administered questionnaires (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire : EORC QLQ-PR25 V3) 3 years
Secondary Quality of life of the participants Quality of life will be assessed using self-administered questionnaires (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire : EORTC QLQ-PR253) by patients 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A